BIO Asia-Taiwan 2026 unites 60 countries, sets participation records
BIO Asia–Taiwan 2026 concluded on July 19, setting records with 150,000 visits from 60 countries and 900 exhibitors. Chairman Johnsee Lee highlighted Taiwan's biotech revenue of NT$800 billion and its evolution into a global partner. The event facilitated over 10,000 partnering meetings and key agreements, including one between Mabion and KriSan Biotech.
*this image is generated using AI for illustrative purposes only.
BIO Asia–Taiwan 2026 concluded successfully on July 19, setting new benchmarks for international engagement with participation from nearly 60 countries and recording almost 150,000 visits. The event, jointly organized by Taiwan Bio Industry Organization (Taiwan BIO) and the Biotechnology Innovation Organization (BIO), underscored Taiwan's emergence as a globally connected biotechnology hub and a trusted partner to the international industry. Under the theme "Asian Inspiration, Global Impact", the exhibition brought together 22 national delegations, 900 exhibitors, and 2,300 booths, establishing a new record for attendance.
Taiwan's Biotech Ecosystem
BIO Asia–Taiwan Chairman Johnsee Lee highlighted that Taiwan's strategic location in the Asia-Pacific region, combined with its thriving electronics and biotechnology sectors, has established the country as a key biotech hub. The biotechnology sector now generates over NT$800 billion (US$25 billion) in annual revenue. Lee noted that the ecosystem has evolved from being home-grown ("In Taiwan") to expanding overseas ("From Taiwan") and now positioning itself as the global biotech industry's partner of choice ("With Taiwan").
Conference Highlights
The conference attracted more than 3,500 biotech professionals, with international attendance and speaker participation reaching record highs. BIO Partnering surpassed 10,000 scheduled meetings, serving as a gateway for global companies seeking R&D collaborations, CDMO contracts, investment opportunities, and licensing partnerships in Asia. The event hosted 16 national pavilions and 10 regional collaboration forums.
Strategic Partnerships and Awards
Several international partnerships were facilitated during the event, including the signing of a Master Service Framework Agreement between Poland's Mabion and Taiwan's KriSan Biotech. To recognize significant contributions to the industry in Asia, BIO Asia–Taiwan presented the BIO Asia Award. Now in its third year, the recipients included Professor Masatoshi Hagiwara of Kyoto University, Japan, as the Individual Award winner, and AstraZeneca as the Organization Award recipient.
Investment and Future Outlook
The Investment Summit brought together more than 100 international investors, venture capital firms, and financial institutions to support Asia's predominantly SME-driven biotech sector. The Taiwan Stock Exchange and Hong Kong Exchanges and Clearing introduced their biotech listing frameworks and market advantages. Lee stated that the success of BIO Asia–Taiwan 2026 goes beyond record-breaking numbers, expanding Taiwan's global connections and showcasing its healthcare advances and innovation capabilities.
| Metric | Figure |
|---|---|
| Countries represented | Nearly 60 |
| Exhibitors | 900 |
| Booths | 2,300 |
| Visits | Almost 150,000 |
| National delegations | 22 |
| National pavilions | 16 |
| Biotech professionals | More than 3,500 |
| Partnering meetings | Over 10,000 |
| Regional collaboration forums | 10 |
| Annual biotech revenue | Over NT$800 billion (US$25 billion) |
How will the 'With Taiwan' strategy influence the volume of cross-border licensing deals and CDMO contracts over the next year?
What specific regulatory incentives are Taiwan and neighboring Asian markets introducing to capitalize on this increased international engagement?
To what extent will the integration of Taiwan's electronics sector accelerate the commercialization of AI-driven drug discovery tools showcased at the event?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
